Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
The gut microbiome and its resistome as predictors of clinical infections and phenotypic antibiotic resistance in hematopoietic stem cell transplant recipients.
Identification of Clinical and Genomic Features Associated with SARS-CoV-2 Reinfections.
Clusters of post-acute COVID-19 symptoms: a latent class analysis across 9 databases and 7 countries.
2025 update of the drug resistance mutations in HIV-1.
Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance.
SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial).
Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trial.
Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial.
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.
Non-canonical HIV drug resistance mutations: need to close existing gaps.